Similar articles

• Heparin-induced thrombocytopenia and cardiovascular diseases.

  Das P, Ziada K, Steinhubl SR, Moliterno DJ, Hamdalla H, Jozic J, Mukherjee D. Das P, et al. Am Heart J. 2006 Jul;152(1):19-26. doi: 10.1016/j.ahj.2005.10.005. Am Heart J. 2006. PMID: 16824828 Review. No abstract available.
• [Heparin-induced thrombocytopenia].

  Cruz-González I, Sánchez-Ledesma M, Sánchez PL, Jang IK. Cruz-González I, et al. Rev Esp Cardiol. 2007 Oct;60(10):1071-82. doi: 10.1157/13111239. Rev Esp Cardiol. 2007. PMID: 17953929 Review. Spanish.
• Heparin-induced thrombocytopenia: what clinicians need to know.

  Chong BH, Isaacs A. Chong BH, et al. Thromb Haemost. 2009 Feb;101(2):279-83. Thromb Haemost. 2009. PMID: 19190810 Review. No abstract available.
• Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.

  Lubenow N, Greinacher A. Lubenow N, et al. J Thromb Thrombolysis. 2000 Nov;10 Suppl 1:47-57. doi: 10.1023/a:1027333320023. J Thromb Thrombolysis. 2000. PMID: 11155194 Review. No abstract available.
• [Heparin-induced thrombocytopenia].

  Christoffersen C, Lethagen S, Gøtze JP. Christoffersen C, et al. Ugeskr Laeger. 2009 Feb 16;171(8):612-5. Ugeskr Laeger. 2009. PMID: 19284907 Danish.